The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, China.
J Oral Pathol Med. 2011 Aug;40(7):521-4. doi: 10.1111/j.1600-0714.2011.01029.x. Epub 2011 Apr 5.
Oral lichen planus (OLP) is generally accepted as a chronic and T-cell-mediated autoimmune disease, whose immunopathogenesis may involve antigen presentation, T-cell activation and migration as well as, possibly, tumor necrosis factor-alpha (TNF-α)-induced keratinocytes apoptosis. However, present treatment options for OLP are far from being satisfactory. Recent advances in understanding the pathogenesis of OLP, progress in biologics, and the success of biologic therapies in OLP indicate that biologic agents are facing expanding indications in OLP. In this review, we mainly discuss the role of T cells in the pathogenesis of OLP and several biologic therapies that directly and/or indirectly target T cells to treat OLP.
口腔扁平苔藓（OLP）通常被认为是一种慢性、T 细胞介导的自身免疫性疾病，其免疫发病机制可能涉及抗原呈递、T 细胞激活和迁移，以及可能的肿瘤坏死因子-α（TNF-α）诱导的角质形成细胞凋亡。然而，目前 OLP 的治疗选择远不能令人满意。对 OLP 发病机制的理解、生物制剂的进展以及生物疗法在 OLP 中的成功表明，生物制剂在 OLP 中的适应证正在不断扩大。在这篇综述中，我们主要讨论了 T 细胞在 OLP 发病机制中的作用，以及几种直接和/或间接针对 T 细胞治疗 OLP 的生物疗法。
